tert-butyl 3-(2-ethoxy-2-oxoethoxy)azetidine-1-carboxylate | 1227381-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: tert-butyl 3-(2-ethoxy-2-oxoethoxy)azetidine-1-carboxylate
• CAS: 1227381-84-1
• 化学式: C₁₂H₂₁NO₅
• 分子量: 259.302
• InChiKey: XMJMSJRCQIXYQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  348.4±32.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(2-ethoxy-2-oxoethoxy)azetidine-1-carboxylate 在 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 0.17h， 以36%的产率得到1-Boc-(3-羧基甲氧基)氮杂丁烷
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS
  [FR] COMPOSÉS ET PROCÉDÉS DE DÉGRADATION CIBLÉE DE KRAS

  摘要：

  本发明描述了双功能化合物，其可用作Kirsten ras肉瘤蛋白（KRas或KRAS）的调节剂。特别是，本公开的杂双功能化合物在一端包含一个与Von Hippel-Lindau E3泛素连接酶结合的部分，在另一端包含一个与KRas结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本发明公开的杂双功能化合物展示了与目标蛋白降解/抑制相关的广泛药理活性。可通过本发明公开的化合物和组合物治疗或预防由目标蛋白异常调节引起的疾病或失调。

  公开号：

  WO2021207172A1
• 作为产物：
  描述：

  1-Boc-3-氮杂环丁酮 在 甲醇 、 dirhodium tetraacetate 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 tert-butyl 3-(2-ethoxy-2-oxoethoxy)azetidine-1-carboxylate
  参考文献：
  名称：

  TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

  摘要：

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。

  公开号：

  US20180125821A1

文献信息

• WO2021011913A5
  申请人：——

  公开号：WO2021011913A5

  公开（公告）日：2023-07-25
• [EN] TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE<br/>[FR] PROTACS CIBLANT LA PROTÉINE TAU ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：ARVINAS INC

  公开号：WO2018102067A2

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
• [EN] TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT LA PROTÉINE TAU ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2021011913A1

  公开（公告）日：2021-01-21

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.
• HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE
  申请人：CHDI Foundation, Inc.

  公开号：US20230159531A1

  公开（公告）日：2023-05-25

  Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。